OA12431A - Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. - Google Patents
Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. Download PDFInfo
- Publication number
- OA12431A OA12431A OA1200300119A OA1200300119A OA12431A OA 12431 A OA12431 A OA 12431A OA 1200300119 A OA1200300119 A OA 1200300119A OA 1200300119 A OA1200300119 A OA 1200300119A OA 12431 A OA12431 A OA 12431A
- Authority
- OA
- OAPI
- Prior art keywords
- oxidized
- médicament
- proteins
- binding
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10051983A DE10051983A1 (de) | 2000-10-20 | 2000-10-20 | Inhibierung der pathogenen Wirkung oxidierter Proteine |
DE2001148624 DE10148624A1 (de) | 2001-10-02 | 2001-10-02 | Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten |
Publications (1)
Publication Number | Publication Date |
---|---|
OA12431A true OA12431A (en) | 2006-04-19 |
Family
ID=26007431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
OA1200300119A OA12431A (en) | 2000-10-20 | 2001-10-19 | Oxidized protein, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins or from the inhibition thereof. |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1994941A3 (el) |
JP (1) | JP4881535B2 (el) |
AP (2) | AP2781A (el) |
AT (1) | ATE406908T1 (el) |
AU (1) | AU2002215032A1 (el) |
CA (1) | CA2453140C (el) |
CY (1) | CY1110418T1 (el) |
DE (1) | DE50114289D1 (el) |
DK (1) | DK1328289T3 (el) |
ES (1) | ES2307662T3 (el) |
HK (1) | HK1057857A1 (el) |
OA (1) | OA12431A (el) |
PT (1) | PT1328289E (el) |
WO (1) | WO2002032445A2 (el) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2523357C (en) * | 2003-04-25 | 2015-07-14 | Hamburger Stiftung Zur Foerderung Von Wissenschaft Und Kultur | Treatment of hi-virus infections with oxidised blood proteins |
JP5416971B2 (ja) | 2005-09-16 | 2014-02-12 | コーネル リサーチ ファウンデイション インコーポレイテッド | Cd36の発現を減少させる方法 |
JP2010235447A (ja) * | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
DE102010043733A1 (de) | 2010-11-10 | 2012-05-10 | Oxprotect Gmbh | Unbeladene PEGylierte Liposomen zur Verwendung als Arzneimittel zur Prophylaxe und Therapie von hämorrhagischen und thrombo- embolischen Erkrankungen |
DE102011003944A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Detektion und Entfernung von missgefalteten Proteinen/Peptiden |
DE102011003936A1 (de) | 2011-02-10 | 2012-08-16 | Oxprotect Gmbh | Verwendung von Proteinen/Peptiden, welche an GRP78 (BIP) binden, in Labormethoden zum Monitoring von Thrombozyten-Aggregationshemmern |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3819923A1 (de) * | 1988-06-11 | 1989-12-21 | Behringwerke Ag | Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung |
US5192264A (en) * | 1989-10-06 | 1993-03-09 | The Beth Israel Hospital Association | Methods and apparatus for treating disease states using oxidized lipoproteins |
CA2067364A1 (en) * | 1989-10-06 | 1991-04-07 | Eric T. Fossel | Oxidized lipoproteins and methods for their preparation |
US5358707A (en) * | 1990-01-08 | 1994-10-25 | Schering Corporation | Oxidized variants of GM-CSF |
AU8305691A (en) * | 1990-07-18 | 1992-02-18 | Beth Israel Hospital Association, The | Method for treating viral infections using oxidized lipoproteins |
EP0728019A4 (en) | 1993-11-08 | 1999-07-07 | Peptide Delivery Systems Pty L | MARKED DIAGNOSTIC COMPOSITIONS AND METHODS OF USE THEREOF |
RU2089179C1 (ru) * | 1995-12-14 | 1997-09-10 | Закрытое акционерное общество "ВАМ" | Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования |
ES2299186T3 (es) | 1997-06-20 | 2008-05-16 | LEUVEN RESEARCH & DEVELOPMENT VZW | Ensayos, anticuerpos y patrones para detectar lipoproteinas de baja densidad oxidadas y modificadas con mda. |
GB9806632D0 (en) * | 1998-03-28 | 1998-05-27 | Stevenson Robert | Peptide factor |
AU1243500A (en) * | 1998-11-06 | 2000-05-29 | Emory University | Biomarkers for oxidative stress |
DE10045047A1 (de) * | 2000-09-12 | 2002-03-21 | Beate Kehrel | Arzneimittel enthaltend aktiviertes Antithrombin III |
-
2001
- 2001-10-19 PT PT01983562T patent/PT1328289E/pt unknown
- 2001-10-19 CA CA2453140A patent/CA2453140C/en not_active Expired - Fee Related
- 2001-10-19 AP AP2009004857A patent/AP2781A/xx active
- 2001-10-19 EP EP08012302A patent/EP1994941A3/de not_active Withdrawn
- 2001-10-19 EP EP01983562A patent/EP1328289B1/de not_active Expired - Lifetime
- 2001-10-19 DK DK01983562T patent/DK1328289T3/da active
- 2001-10-19 AU AU2002215032A patent/AU2002215032A1/en not_active Abandoned
- 2001-10-19 ES ES01983562T patent/ES2307662T3/es not_active Expired - Lifetime
- 2001-10-19 AP APAP/P/2003/002795A patent/AP2034A/en active
- 2001-10-19 JP JP2002535683A patent/JP4881535B2/ja not_active Expired - Fee Related
- 2001-10-19 AT AT01983562T patent/ATE406908T1/de active
- 2001-10-19 DE DE50114289T patent/DE50114289D1/de not_active Expired - Lifetime
- 2001-10-19 OA OA1200300119A patent/OA12431A/en unknown
- 2001-10-19 WO PCT/EP2001/012129 patent/WO2002032445A2/de active IP Right Grant
-
2004
- 2004-01-05 HK HK04100053.0A patent/HK1057857A1/xx not_active IP Right Cessation
-
2008
- 2008-11-19 CY CY20081101332T patent/CY1110418T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2453140A1 (en) | 2002-04-25 |
AP2781A (en) | 2013-10-31 |
EP1328289A2 (de) | 2003-07-23 |
AP2003002795A0 (en) | 2003-06-30 |
CY1110418T1 (el) | 2015-04-29 |
WO2002032445A2 (de) | 2002-04-25 |
JP2004511526A (ja) | 2004-04-15 |
AP2009004857A0 (en) | 2009-06-30 |
CA2453140C (en) | 2016-01-05 |
DK1328289T3 (da) | 2008-12-15 |
DE50114289D1 (de) | 2008-10-16 |
ATE406908T1 (de) | 2008-09-15 |
EP1994941A2 (de) | 2008-11-26 |
EP1328289B1 (de) | 2008-09-03 |
ES2307662T3 (es) | 2008-12-01 |
JP4881535B2 (ja) | 2012-02-22 |
PT1328289E (pt) | 2008-12-10 |
HK1057857A1 (en) | 2004-04-23 |
AU2002215032A1 (en) | 2002-04-29 |
AP2034A (en) | 2009-08-28 |
WO2002032445A3 (de) | 2003-04-17 |
EP1994941A3 (de) | 2012-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Woulfe | REVIEW ARTICLES: Platelet G protein-coupled receptors in hemostasis and thrombosis | |
US6280731B1 (en) | Antithrombotic agent and anti-von willebrand factor monoclonal antibody | |
CZ301524B6 (cs) | Polypeptid z H. medicinalis, zpusob jeho prípravy a použití, farmaceutický prostredek, polynukleotid, expresní vektor, hostitelská bunka, protilátka a její použití | |
CN110075294A (zh) | 用于治疗与masp-2依赖性补体活化相关的状况的方法 | |
US7273925B1 (en) | Methods and products for regulating lectin complement pathway associated complement activation | |
Lima et al. | From patients to platelets and back again: pharmacological approaches to glycoprotein VI, a thrilling antithrombotic target with minor bleeding risks | |
EP1140171A1 (en) | Methods and products for regulating lectin complement pathway associated complement activation | |
US8034769B2 (en) | Oxidized proteins and oxidized protein inhibitor compositions and methods of use thereof | |
CA2453140C (en) | Oxidized proteins, their biological activity, and therapeutic and diagnostic measures, which are derived from the active mechanism, from the use of these proteins and from the inhibition thereof | |
PL204449B1 (pl) | DNA kodujący glikoproteinę VI | |
US20110236455A1 (en) | Novel Regulators of the Innate Immune System | |
WO2007011682A2 (en) | Methods and reagents for screening new drugs and for treating ion pump associated disorders and diseases | |
KR20010102130A (ko) | 지혈 및 면역기능에 사용하기 위한 억제제 | |
US20060153831A1 (en) | Antithrombosis enzyme from the snake venom of Agkistrodon acutus | |
JP5232818B2 (ja) | 酸化ldl受容体に対する抗体を含んでなる医薬組成物 | |
CN111870700B (zh) | 十八烷基化修饰的r18-7aa多肽及其衍生多肽的应用 | |
JP2006516024A (ja) | α1β1インテグリンの誘導性リガンドおよび使用 | |
DE10148624A1 (de) | Oxidierte Proteine - ihre biologische Wirkung, sowie therapeutische und diagnostische Maßnahmen, die sich aus dem Wirkmechanismus, dem Einsatz dieser Proteine oder deren Inhibierung ableiten | |
WO1998016548A1 (en) | Thrombin receptor peptides and uses thereof | |
WO2016021894A1 (ko) | Cd9 항체를 유효성분으로 함유하는 세포노화 또는 노화 관련 질환 예방 또는 치료용 약학조성물 | |
O'Sullivan | An investigation of the role of ACTN1 in platelet formation and of platelet function in myeloma | |
Lo | Investigating the functional roles of NBEAL2 in megakaryocytes and platelets | |
Visconte | Roles of Amyloid Precursor Protein in Platelet Function | |
Szewczyk | BIOTECHNOLOGICAL INVENTION OF CALOXINS-A NOVEL CLASS OF ALLOSTERIC INHIBITORS SPECIFIC FOR PLASMA MEMBRANE CALCIUM PUMP ISOFORMS | |
FR2895262A1 (fr) | Inhibition de la reponse immunitaire anti-fviii |